Thanks Jov88,There is no mistaking the fact that the azer-cel...

Thanks Jov88,
There is no mistaking the fact that the azer-cel data in the phase 1 highlights the significant increase in the overall response rate for Car-T relapse patients with Non-Hodgkin lymphoma compared to all other patients on a range of treatments. Its not just the ORR but importantly and critically the complete response and duration of response > than 6 months.

I'm pretty sure that its not only Imugene and posters on HC that have noticed. As you said, its most likely that every BP with skin in the game and with classwide black box warnings for auto Car-T have had board meetings around their Car-T strategy moving forward. All eyes are on the confirmatory study in DLBCL for patients relapsed after autologous Car-T therapies.

Whether there is a "priming that occurs from auto CAR-T that assists with azer-cel's efficacy" is unknown, but the synergy appears to be unmistakeable. I am confident that Imugene believes that similar priming or synergy can be achieved with CF33 and refer specifically to the data already generated in preclinical combination studies of azer-cel plus oncarlytics showing 100% killing of triple negative breast cancer and gastric cancer lines. We have raised the prospect that similar priming or synergy may be achieved with the use of azer-cel as a bridging therapy for patients awaiting their auto Car-T knowing that a significant number won't otherwise make it or will be further immuno compromised by additional chemotherapy.

We shouldn't make the mistake of believing that allogeneic Car-T therapies is the answer in itself. Likewise with autologous Car-T, allogeneic Car-T have an issue with lack of durability and patient relapse. Imugene, however, have peered into the data without rose coloured glasses and found an exceptional path forward.